University of Ioannina
Κυτταρογενετική και μοριακή κυτταρογενετική μελέτη των νεοπλασιών του προστάτη
Abstract
dc:descriptionThe most common cancer in men is prostate cancer followed by lung cancer, the second leading cause of death in men.One of the prevalent questions concerning all benign diseases of the prostate is whether their presence increases the risk of prostate cancer. Benign prostatic hyperplasia (Benign Prostatic Hyperplasia, BPH) and prostate carcinoma (Prostate Cancer, CaP) are common urologic diseases in the elderly and there is enough evidence supporting the view that up to a degree there is co-relationship between benign prostatic hyperplasia and prostate cancer.All relevant studies in biopsy material showing that benign prostatic hyperplasia and prostate cancer coexist quite often. Epidemiological studies also show a correlation between carcinomas and benign prostate hyperplasia, with most of them indicating that there is only a small increase in the risk of tumors in patients with benign prostatic hyperplasia.However, despite the similarities and common elements, there is enough strong evidence supporting the view that benign hyperplasia and carcinoma of the prostate are not co-related and that the presence of prostatic hyperplasia does not increase the risk of cancer in the gland. Also, the existing genetic information concerning the benign diseases of the prostate is poor despite the indicated relationship to the cancer.The purpose of this study is to investigate the presence and frequency of a number of fusion genes in prostate carcinomas, the presence or absence of the corresponding fusion genes in benign hyperplasia and the possibility of using fusion genes as diagnostic markers for prostate cancer.116 samples of benign hyperplasia were studied, 66 carcinomas of the prostate samples and 66 urine samples with molecular analysis, and in 38 samples of benign hyperplasia and 12 samples of prostate carcinomas was further detection of the fusion gene TMPRSS2-ERG with the technique of fluorescent in-situ hybridization (FISH).The interpretation and evaluation of the results showed that the frequency of the presence of the fusion gene TMPRSS2-ERG in tumors is in the levels of 50% and the remaining fusion genes rates seem to be very small. These rates are independent of the method for identification and were in agreement with literature data.There is no correlation between the degree of histological malignancy (grade) of the Gleason process and of the presence or absence of the fusion gene TMPRSS2-ERG. An important finding was the detection of the fusion gene in benign hyperplasia and the difference exhibited in gene expression by specific hyperplasia, which indicates that possible heterogeneity exists in between hyperplasia, as well as the fact that part of hyperplasia exhibit some genetic alterations that are common to those observed in a group of carcinomas of the prostate. The detection of the fusion gene by FISH in benign hyperplasia and especially the confirmation of its presence is a finding that has not yet been published and therefore requires further investigationAn outstanding finding was the possibility of detection of the fusion gene TMPRSS2-ERG in sediment cells in urine and the positive correlation with the presence of malignancy in the biopsies, where it is concluded that it may be used as non-invasive diagnostic marker.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Velaeti, Stamatia
- Βελαέτη, Σταματία
Subjects
dc:subject × 18- Καρκίνος προστάτη
- Καλοήθης υπερπλασία προστάτη
- Χιμαιρικά γονίδια
- Διαγνωστικοί δείκτες
- Μοριακή ανάλυση
- Μέθοδος FISH
- Prostate cancer
- Benign prostatic hyperplasia
- Fusion genes
- TMPRSS2-ERG
- Cancer specific biomarkers
- Molecular analysis
- Molecular cytogenetics analysis
- FISH method
- Ιατρική και Επιστήμες Υγείας
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29041